Senior CMC Program Manager
Immatics
Summary
We are seeking a Senior Program Manager, CMC to lead and coordinate cross-functional Chemistry, Manufacturing, and Controls (CMC) activities within a cell therapy development and manufacturing environment. The Senior Program Manager, CMC will drive planning, execution, and integration across manufacturing, analytical, quality, regulatory, and supply chain functions to support clinical development and commercialization goals. This role serves as a strategic partner across technical and operational teams, ensuring alignment, proactive risk management, and readiness for key milestones, including regulatory submissions and commercial manufacturing.
Job description
In this role you will:
- Develop and maintain CMC program plans, timelines, risk registers, trackers, and reporting tools to support integrated program execution
- Manage CMC deliverables, milestones, and critical paths while ensuring alignment with overarching development program timelines
- Lead and facilitate cross-functional CMC meetings, including agenda development, documentation, action tracking, and follow-up activities
- Drive collaboration across Manufacturing, Process Development, Analytical Development, Quality, Regulatory, Supply Chain, and Patient Operations teams
- Coordinate and oversee activities with external vendors, contractors, CMOs, and CDMOs
- Support strategic planning, governance, and decision-making activities with department leaders and senior management
- Contribute to continuous improvement of CMC program management tools, processes, onboarding, and operational best practices
Requirements
- Bachelor's degree in life sciences, medicine, immunology, oncology, pharmacy, health sciences, or a related field
- 7 years of experience within biotechnology, pharmaceutical, or oncology-focused clinical development environments
- Demonstrated experience in CMC program/project management or complex project leadership, leading cross-functional CMC activities, including manufacturing, quality, analytical, and regulatory operations
- Academic or industry experience in cell and gene therapy, immunology/oncology, or bioprocessing/manufacturing sciences
- Advanced degree such as a Masters or PhD in life sciences, medicine, immunology, oncology, pharmacy, health sciences, or a related field
- Experience supporting late-stage CMC programs in immunology, oncology, or cell and gene therapy
- Proven experience managing complex programs and critical paths across multiple technical and operational functions
- Proficiency with project management tools, dashboards, and reporting systems in regulated environments
- Proven leadership, stakeholder management, and organizational skills with the ability to manage competing priorities in fast-paced environments
- Advanced ability to identify risks, drive decision-making, and implement process improvements across cross-functional teams
- Experience coordinating external vendors, CMOs, CDMOs, or consulting partners
- Strong communication and presentation skills with experience supporting senior leadership discussions and strategic planning
Benefits
- Health Insurance
- Dental Insurance
- Vision Insurance
- 4 weeks vacation
- 12 paid holidays
- 7 days sick time
- Life Insurance
- Short-term Disability
- Long-term Disability
- 401(k) Matching
- Parental Leave
- Accident Insurance
- Hospital Indemnity Insurance
- Critical Illness Insurance
- Identity Theft Protection
- Pet Insurance
Company overview
Immatics is a clinical-stage biotechnology company and the global leader in precision targeting of PRAME (Preferentially Expressed Antigen in Melanoma), a cancer target expressed in more than 50 different cancer types. Founded in 2000 as a spin-off from the University of Tübingen's Department of Immunology, the company has grown into a publicly traded entity (NASDAQ: IMTX) with operations in Germany and the United States. Immatics specializes in developing T-cell redirecting immunotherapies, including TCR T-cell therapies and TCR bispecifics, for the treatment of solid tumors. The company's proprietary XPRESIDENT™ technology platform enables the identification of tumor-associated peptides (TUMAPs) with unprecedented sensitivity, allowing for the development of highly specific cancer immunotherapies. With a robust clinical pipeline focused on PRAME-targeting therapies, Immatics is advancing multiple programs including IMA203 (anzutresgene autoleucel) for PRAME-positive solid tumors, IMA402 PRAME bispecific, and IMA401 MAGEA4/8 bispecific. The company's innovative approach combines mass spectrometry, genomics, biochemistry, and immunology to create novel cancer treatments that address significant unmet medical needs in oncology.